LLY

Lilly Eli & Co

825.45

4.41+0.54%

After Hours: 825.55 +0.10 +0.01%19:59 10/24 EDT

Daily

Weekly

Monthly

Quarterly

Yearly

OPEN/PREV CLOSE815.21/821.04

TODAY RANGE812.50-834.15

VOL2.21M

MARKET CAP781.25B

52 WEEK RANGE622.41-931.66

AVG VOL (3M)4.57M

% TURNOVER0.23%

TURNOVER--

P/E (TTM)53.92

% RANGE2.63%

EPS(TTM)15.31

P/E(FORWARD)37.44

P/B42.77

BVPS19.30

DIVIDEND6.00

P/S17.36

BETA--

DIV YIELD0.73%

FREE FLOAT MKT CAP779.51B

SHARES OUTSTANDING946.46M

NEXT EARNINGS02/04-02/10

FREE FLOAT944.35M

LOT SIZE1

EX-DATE08/15/2025

News

Press Releases

Financial Reports

Profile

TipRanks·1d ago
M&A News: Eli Lilly’s (LLY) $262M Acquisition of Adverum Bolsters Gene Therapy Push
TipRanks·1d ago
Eli Lilly (LLY) Buys Gene Therapy Developer Adverum for $261 Million
Seeking Alpha·1d ago
Catalyst Watch: Trump-Xi, Fed meeting, Honeywell spinoff, and Amazon headlines busy earnings week
Seeking Alpha·1d ago
Novo Nordisk: Decade-Low Valuation Meets A Billion-Patient Market
TipRanks·1d ago
Midday Fly By: Intel, Ford report Q3 beats
Seeking Alpha·1d ago
Over 80% of companies beat EPS estimates this week: Earnings Scorecard
NASDAQ·1d ago
Trade Truce Hope: How US-China Talks Could Boost Healthcare ETFs
Dow Jones·1d ago
Eli Lilly Agrees to Acquire Adverum Biotechnologies
TipRanks·1d ago
Leerink Partners Keeps Their Hold Rating on Eli Lilly & Co (LLY)
Seeking Alpha·1d ago
Lilly to acquire Adverum for up to $12.47 per share in cash and CVRs
TipRanks·1d ago
Eli Lilly to acquire Adverum Biotechnologies for up to $12.47 per share
Dow Jones·1d ago
*Eli Lilly Says Transaction Is Expected to Close in the 4Q >LLY
Dow Jones·1d ago
*Eli Lilly: Offer Also Includes 1 Non-Transferrable Contingent Value Right Entitling Holder to Receive Up to an Additional $8.91 Per CVR in Cash Upon the Achievement of 2 Milestones, for Total Potential Consideration of Up to $12.47/Shr >LLY
Seeking Alpha·1d ago
Eli Lilly, Incyte post new late-stage trial data for Olumiant in adolescents with hair loss
Dow Jones·1d ago
*Eli Lilly to Launch Tender Offer to Acquire All Outstanding Shares of Adverum for $3.56/Shr >LLY

Same Industry

Name/Symbol

Change%

Price

Lilly Eli & Co

LLY

+0.54%

825.45

McKesson

MCK

+1.10%

801.67

Biogen Inc

BIIB

-0.13%

149.89

Amgen Inc

AMGN

-0.39%

291.76

Bristol-Myers Squibb Company Celegne Contingent Value Rights

CELG-RT

+17.89%

0.0336

Shire

SHPG

179.20

Celgene

CELG

108.24

Therapeuticsmd Inc

TXMD

-1.53%

1.29

Johnson & Johnson

JNJ

-1.08%

190.40

Abbvie Inc

ABBV

-0.11%

227.99

Zoetis Inc

ZTS

-0.31%

145.94

Gilead Sciences Inc

GILD

+0.17%

120.94

Novo-Nordisk A/S

NVO

-0.51%

52.96

Bristol-Myers Squibb Co

BMY

0.00%

43.83

Alexion Pharms

ALXN

+1.70%

182.50

Pfizer

PFE

+0.36%

24.76

Sanofi FR

SNY

+4.28%

51.64

Sanofi FR

GCVRZ

0.00%

0.8711

Novartis

NVS

-0.97%

130.36

Dr Reddys Labs

RDY

-0.27%

14.58

GSK PLC

GSK

-5.05%

43.24

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.